CompletedPhase 2NCT00521118
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
Studying Complete hydatidiform mole
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Group
- Principal Investigator
- Raymond OsborneNRG Oncology
- Intervention
- Laboratory Biomarker Analysis(other)
- Enrollment
- 64 enrolled
- Eligibility
- FEMALE
- Timeline
- 2007 – 2015
Study locations (29)
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States
- Stanford Cancer Institute, Palo Alto, California, United States
- UCSF Medical Center-Mount Zion, San Francisco, California, United States
- Olive View-University of California Los Angeles Medical Center, Sylmar, California, United States
- Colorado Gynecologic Oncology Group, Aurora, Colorado, United States
- University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
- Hartford Hospital, Hartford, Connecticut, United States
- The Hospital of Central Connecticut, New Britain, Connecticut, United States
- Memorial University Medical Center, Savannah, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- Borgess Medical Center, Kalamazoo, Michigan, United States
- Bronson Methodist Hospital, Kalamazoo, Michigan, United States
- West Michigan Cancer Center, Kalamazoo, Michigan, United States
- Women's Cancer Center of Nevada, Las Vegas, Nevada, United States
- Virtua Memorial, Mount Holly, New Jersey, United States
- +14 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00521118 on ClinicalTrials.gov